ArticleBMC complementary medicine and therapies2025
Commiphora myrrha resin extract-modulated cytochrome P-450 2C9 enzyme expression in cultured Hep G2 cells is associated with resin extract-derived metabolites binding to Pregnane X receptor.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Natural Products and Traditional Chinese Medicine in Hepatocellular Carcinoma: From Pharmacological Mechanisms to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review.Journal of the Chinese Medical Association : JCMA · 2026Review
- Preliminary Insights into the Non-Volatile Constituents ofPlants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe use of natural health products (NHP) is constantly increasing worldwide. Among the most NHP consumed in the Arabian Peninsula are the resins of Commiphora myrrha (C. myrrha) tree. Consumption of C. myrrha may result in herb-drug interactions mediated by drug-metabolizing cytochrome P-450 (CYP) enzymes in the liver, which could lead to serious health consequences for patients. This study aims to determine the herb-drug interactions based on the induction of predominant CYP 2C9 by a non-toxic boiled aqueous extract of C. myrrha and to unveil the potential involvement of xenobiotic-sensing nuclear receptors such as transcription factor Pregnane X Receptor (PXR) in CYP 2C9 induction, and to predict the molecular interactions of PXR with C. myrrha-derived metabolite(s).
methodsCytotoxic effect of boiled aqueous extract of C. myrrha resins in cultured liver carcinoma Hep G2 cells was assessed using MTT assay. CYP 2C9 gene and protein expression levels were evaluated using reverse transcription-quantitative polymerase chain reaction and Western blot. Nuclear receptor binding assays, chemical analysis and molecular docking prediction were performed using specific kits, liquid chromatography-mass spectrometry time-of-flight, and in silico software, respectively.
resultsTested at low concentrations (0.01-10 µg/mL) devoid of anti-proliferative effects, boiled C. myrrha resin aqueous extract upregulated CYP 2C9 gene and protein expressions in a dose-dependent manner, reaching a mean expression level exceeding 3.0-fold change in Hep G2 cells, compared with the basal level expressed in untreated cells. Furthermore, the use of the nuclear receptor binding assays confirmed the binding between C. myrrha metabolite(s) and PXR, while no binding to the other xenobiotic-sensing nuclear receptor, the constitutive androstane receptor (CAR), was observed. Chemical analysis and computational molecular docking using in silico studies revealed that a few C. myrrha resin-derived metabolites are strongly bound to PXR. In particular, the identified metabolite named commic acid E exhibited a predicted molecular docking score close to that of a native PXR ligand, suggesting C. myrrha metabolite(s) as potential PXR agonists.
conclusionsAlthough in vivo studies are needed, this study cautions patients, healthcare providers, and governmental regulators against the consumption of C. myrrha preparations with a high potential for herb-drug interactions through drug-metabolizing CYP 2C9 enzyme induction, which could affect drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.